Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry.
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
21
07
2022
received:
24
02
2022
accepted:
25
07
2022
pubmed:
25
8
2022
medline:
25
8
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes. Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death. One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities. This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
Identifiants
pubmed: 36000538
doi: 10.1002/acr2.11495
pmc: PMC9539246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
948-953Subventions
Organisme : American College of Rheumatology
Organisme : European Alliance of Associations for Rheumatology
Informations de copyright
© 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Safiri S, Kolahi AA, Cross M, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990-2017: a systematic analysis of the global burden of disease study 2017. Arthritis Rheumatol 2020;72:1916-27.
Robinson PC, Merriman TR, Herbison P, et al. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. Rheumatology (Oxford) 2012;52:118-26.
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-6.
Strangefeld A, Schafer M, Gianfrancesco M, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021;80:930-42.
Grainger R, Machado PM, Robinson PC. Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes. Best Pract Res Clin Rheumatol 2021;35:101657.
Dalbeth N, Robinson PC. Patients with gout: an under-recognised group at high risk of COVID-19. Lancet Rheumatol 2021;3:e317-8.
Tai V, Robinson PC, Dalbeth N. Gout and the COVID-19 pandemic. Curr Opin Rheumatol 2022;34:111-7.
Tardif JC, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 2021;9:924-32.
Schäfer M, Strangfeld A, Hyrich KL, et al. Response to: ‘Correspondence on “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry”’ by Mulhearn et al. Ann Rheum Dis 2021. E-pub ahead of print.
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020;79:859-66.
Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020;79:851-8.
Tam LS, Tanaka Y, Handa R, et al. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. Int J Rheum Dis 2021;24:733-45.
Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2. Arthritis Rheumatol 2020;72:e1-12.
Topless RK, Phipps-Green A, Leask M, et al. Gout, rheumatoid arthritis, and the risk of death related to coronavirus disease 2019: an analysis of the UK Biobank. ACR Open Rheumatol 2021;3:333-40.
Wallace ZS, Bhana S, Hausmann JS, et al. The rheumatology community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. Rheumatology (Oxford) 2020;59:1204-6.
Robinson PC, Yazdany J, Machado PM. Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. Curr Opin Rheumatol 2021;33:111-6.
Liew JW, Bhana S, Costello W, et al. The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology 2021;60:353-8.
RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704.
Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum 2020;50:S11-6.
Iftimie S, López-Azcona AF, Vallverdú I, et al. First and second waves of coronavirus disease-19: a comparative study in hospitalized patients in Reus, Spain. PLoS One 2021;16:e0248029.
Wolfisberg, Gregoriano, Struja, et al. Comparison of characteristics, predictors and outcomes between the first and second COVID-19 waves in a tertiary care centre in Switzerland: an observational analysis. 2021. URL: https://smw.ch/article/doi/smw.2021.20569.
Bechman K, Yates M, Mann K, et al. Inpatient COVID-19 mortality has reduced over time: results from an observational cohort. PLoS One 2022;17:e0261142.
Kloka JA, Blum LV, Old O, et al. Characteristics and mortality of 561,379 hospitalized COVID-19 patients in Germany until December 2021 based on real-life data. Sci Rep 2022;12:11116.
Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol 2020;16:293-4.
Jatuworapruk K, Grainger R, Dalbeth N, et al. Development of a prediction model for inpatient gout flares in people with comorbid gout. Ann Rheum Dis 2020;79:418-23.
Singh JA, Edwards NL. Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey. Ther Adv Musculoskelet Dis 2020;12:1759720X20966124.
García-Maturano JS, Torres-Ordaz DE, Mosqueda-Gutiérrez M, et al. Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement. Clin Rheumatol 2022. E-pub ahead of print.